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Abstract Trypanosoma brucei rhodesiense is one of the
causative agents of human sleeping sickness, a fatal disease
that is transmitted by tsetse flies and restricted to Sub-
Saharan Africa. Here we investigate two independent lines
of T. b. rhodesiense that have been selected with the drugs
melarsoprol and pentamidine over the course of 2 years,
until they exhibited stable cross-resistance to an unprece-
dented degree. We apply comparative genomics and
transcriptomics to identify the underlying mutations. Only
few mutations have become fixed during selection. Three
genes were affected by mutations in both lines: the
aminopurine transporter AT1, the aquaporin AQP2, and the
RNA-binding protein UBP1. The melarsoprol-selected line
carried a large deletion including the adenosine transporter
gene AT1, whereas the pentamidine-selected line carried a
heterozygous point mutation in AT1, G430R, which ren-
dered the transporter non-functional. Both resistant lines
had lost AQP2, and both lines carried the same point
mutation, R131L, in the RNA-binding motif of UBP1. The
finding that concomitant deletion of the known resistance
genes AT1 and AQP2 in T. b. brucei failed to phenocopy
the high levels of resistance of the T. b. rhodesiense
mutants indicated a possible role of UBP1 in melarsoprol–
pentamidine cross-resistance. However, homozygous
in situ expression of UBP1-Leu131 in T. b. brucei did not
affect the sensitivity to melarsoprol or pentamidine.
Keywords African trypanosomes  Aquaporin 
RNA-binding protein  Purine permease  Pentamidine 
Melarsoprol
Abbreviations
MPXR Melarsoprol–pentamidine cross-resistance
SLT Spliced leader trapping
AQP2 Aquaglyceroporin 2
AT1 Adenosine transporter 1
Tet Tetracycline
UBP1 Uridine-rich binding protein 1
VSG Variant surface glycoprotein
Introduction
Human African trypanosomiasis (HAT, also known as
sleeping sickness) is a fatal disease caused by Try-
panosoma brucei rhodesiense and T. b. gambiense in East-
and West-Africa, respectively. These protozoan parasites
are transmitted by tsetse flies and proliferate extracellularly
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in the bloodstream and lymph of their mammalian hosts,
evading the adaptive immune response through antigenic
variation of their variant surface glycoprotein (VSG) coat.
Ultimately the trypanosomes also infest the cerebrospinal
fluid, causing the ‘sleeping sickness’ syndrome of infected
patients. Trypanosoma brucei has an approximate haploid
genome size of 35 Mb, which can vary up to 25 % [1].
Excluding the kinetoplast (i.e., mitochondrial) DNA leaves
a nuclear core genome of about 26 Mb, divided into 11
megabase-sized chromosomes, where the vast majority of
the predicted[9000 protein-coding genes are located [2].
The treatment of HAT relies on just five drugs. Patients in
the first, hemolymphatic stage are treated with suramin (T.
b. rhodesiense) or pentamidine (T. b. gambiense). In the
second stage, when the trypanosomes have invaded the
central nervous system, melarsoprol or nifurtimox-eflor-
nithine combination therapy (NECT; only for T. b.
gambiense) are used [3]. These drugs are outdated,
impractical, and suffer from severe adverse effects.
Melarsoprol, in particular, causes unacceptable toxicity [4].
Furthermore, melarsoprol treatment failure rates of up to
30 % have been reported throughout sub-Saharan Africa
[5–8]. New drugs that are safe and orally available are
presently in clinical development [9]. Meanwhile, it is
essential to sustain the current drugs in spite of their
shortcomings, which requires an understanding of the
mechanisms of drug resistance. This will also help avoid
cross-resistance between current treatments and those in
development.
The molecular mechanisms of drug resistance have
predominantly been studied in T. b. brucei, which is non-
pathogenic to humans and widely used as a model in
molecular parasitology. A phenomenon that has been
repeatedly observed is melarsoprol–pentamidine cross-re-
sistance (MPXR), i.e., trypanosomes selected for resistance
with a melaminophenyl arsenical turned out to be cross-
resistant to pentamidine and vice versa [10–12]. This
phenomenon was attributed to the finding that the uptake of
melarsoprol and pentamidine into the trypanosomes is
mediated by the same set of transporters: the aminopurine
permease P2 [13, 14], encoded by the gene AT1, and a
high-affinity pentamidine transport activity designated as
HAPT1 [15, 16] recently shown to correspond to the
aquagylceroporin AQP2 [17, 18]. Mutations in these
transporters were described from drug-resistant T. brucei
ssp. isolates from the field [19–21]. In the lab, MPXR was
phenocopied by reverse genetics. Homozygous deletion of
either AT1 or AQP2 resulted in resistance to both melar-
soprol and pentamidine. However, the obtained resistance
factors were only between 2 and 3 for melarsoprol and
pentamidine in AT1 null trypanosomes [22, 23], respec-
tively, and 2 for melarsoprol and 15 for pentamidine in
AQP2 null mutants [17].
Here we investigate two clonal drug-resistant lines of T.
b. rhodesiense that exhibit markedly higher levels of
MPXR than observed after deletion of either AT1 or AQP2.
The lines T. b. rhodesiense STIB900-M and STIB900-P
had been selected in vitro from their drug-susceptible
parent T. b. rhodesiense STIB900 by continuous in vitro
exposure to increasing concentrations of melarsoprol and
pentamidine, respectively, over a period of 24 months [24].
Finally, both lines exhibited a high level of MPXR with
in vitro resistance factors up to 80 (the resistance factor
was defined as IC50 of the selected line divided by the IC50
of the drug-sensitive parent). This phenotype was stable in
the absence of drug pressure and after passage through
mice. An initial genotypic characterization demonstrated
that AT1 had been lost in STIB900-M but was still present
in STIB900-P [24]. Evidently, given the high level of drug
resistance, further mutations must be involved. We have
performed whole genome sequencing and RNA-Seq of the
parental T. b. rhodesiense STIB900 and its resistant
derivatives STIB900-M and STIB900-P, aiming to eluci-
date the molecular mechanisms underlying the
unprecedented level of MPXR by comparative genomics
and transcriptomics.
Materials and methods
T. b. rhodesiense lines
Trypanosoma brucei rhodesiense STIB900 is a derivative
of STIB704, isolated from a male patient at St. Francis
Hospital in Ifakara, Tanzania, in 1981. After several pas-
sages in rodents and a cyclic passage through a tsetse fly
(Glossina morsitans morsitans), a cloned population was
adapted to axenic growth. T. b. rhodesiense STIB900-M
and STIB900-P had been selected independently in vitro
for resistance to melarsoprol and pentamidine, respectively
[24]. Bloodstream-form trypanosomes were propagated
in vitro as described in [20] and adapted from [25]. Cells
were counted with the CASY Cell Counter system
(Roche). Large numbers of trypanosomes for DNA isola-
tion were obtained by inoculating female Naval Medical
Research Institute (NMRI) mice (Harlan Laboratories) with
106 trypanosomes. At peak parasitemia, the trypanosomes
were harvested and separated from the blood cells on
DEAE-cellulose columns [26].
In vitro drug sensitivity
For all the STIB900 lines drug sensitivities were deter-
mined with the Alamar blue assay [27]. T. b. brucei B48
drug sensitivities were determined as described using a
slightly modified protocol [28]. The SoftMax Pro software
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and Prism 5 (GraphPad) were used to calculate 50 %
inhibitory concentrations (IC50) by non-linear regression
fitting to a sigmoidal dose–response curve. All assays were
performed at least three times independently, each in
duplicate or triplicate. The following compounds were
tested, each individually: melarsoprol (Sanofi-Aventis/
WHO), eflornithine (Sanofi-Aventis), DB75 (Immtech),
fexinidazole (DNDi, Geneva), nifurtimox (WHO, Geneva),
suramin (Bayer), pentamidine isethionate, diminazene
aceturate, phenylarsine oxide, aminopurinol, cordycepin,
adenosine arabinoside, and tubercidin (Sigma). Statistical
tests were performed with GraphPad Prism 5.0.
Isolation of nucleic acids
Genomic DNA was isolated by phenol/chloroform extrac-
tion from bloodstream-form trypanosomes propagated in
mice. To check for contamination with mouse DNA we
performed PCR with primers for mouse glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) and mouse cDNA as a
positive control. For each T. b. rhodesiense line, about
60 lg of genomic DNA was prepared for sequencing. Total
RNA was isolated from exponentially growing cultures of
trypanosomes (106 cells/ml) with TRIzol (Life technolo-
gies). Equal amounts of total RNA were pooled from three
independent isolations, and from each pooled sample 12 lg
were used for sequencing.
Spliced leader trapping
Library preparation and RNA-Seq were performed according
to the spliced leader trapping (SLT) protocol [29]. This is a
modification of the standard Illumina protocol that uses the T.
brucei 39 nt spliced leader sequence (which is a peculiarity of
trypanosomatids and gets ligated to the 50 end of every
mRNA) for 2nd strand cDNA synthesis and sequencing. Two
independent experiments were performed: run 1 on the Gen-
ome Analyzer IIx (Illumina) and run 2 on the HiSeq 2000
(Illumina). The Fastq files were read into the Spliced Leader
ADDition (SLADD) program [29] and mapped onto the ref-
erence genome sequence of T. brucei TREU927 [2], using
MAQ [30] with n = 3 and with a read length of C24. Multi-
mapping reads were separated from single mappers by an
alignment quality threshold of 30. Read counts were nor-
malized according to library size and expressed as tags per
million reads (TPM). Statistical analysis for differentially
expressed genes was performed with the DESeq package in R
[31]. DESeq uses a negative binomial distribution and a
shrinkage factor for the distribution’s variance. Only mapped
reads (raw counts) with a stringent quality score of q\ 30 and
data from both performed SLT runs were included.
Whole genome sequencing
Whole genome sequencing of T. b. rhodesiense STIB900
was carried out on the Illumina HiSeq 2000 platform. Two
times 12,243,924 paired-end reads of 76 b were mapped
chromosome-wise to the reference genome T. b. brucei 927
(v5) using MIRA (v3.9.16) [32]. Gene models from the
reference genome T. b. brucei 927 were transferred to the
assembled STIB900 genome using rapid annotation trans-
fer tool (RATT) [33] from the post assembly genome
improvement toolkit (PAGIT) [34] package. Whole gen-
ome sequencing of T. b. rhodesiense STIB900-M and
STIB900-P was carried out on the Genome Sequencer FLX
Titanium by Roche/454. Two shotgun runs per line were
performed. FASTQ format was extracted from .sff files
using ‘SFF converter’ from Galaxy [35]. High-quality
(HQ) reads were mapped to the assembled STIB900 gen-
ome, indexed with word length 13 and skip step 1, using
the program SMALT (ftp.sanger.ac.uk/pub4/resources/
software/smalt). Consensus sequence and variants relative
to the assembled STIB900 genome were identified with
‘mpileup’ from SAMtools [36]. Ad hoc Perl scripts were
used to compare nucleotide variants between the mapped
reads of STIB900-M, STIB900-P, and the assembled
STIB900 genome. For comparison also STIB900 reads
generated on the Roche/454 platform were mapped to the
assembled STIB900 genome. SNPs were called if they had
a read depth of at least five high-quality bases (DP4 C 5)
and a read mapping quality of minimum 20 (mapq C20).
All identified SNPs, indels, and gene deletions were
inspected manually using Artemis [37]. The Roche/454
reads are accessible via the European Nucleotide Archive
(http://www.ebi.ac.uk/ena) under accession number
PRJEB12780.
PCR amplification and Sanger sequencing
The PCR primers to amplify the 3.2 kb AQP2/AQP3 tan-
dem locus were AQP2/3_F (aagaaggctgaaactccacttg) and
AQP2/3_R (tgcactcaaaaacaggaaaaga), annealing at 58 C.
AT1-G430R was amplified from genomic DNA of
STIB900-P with primers AT1_F (gaaatccccgtcttttctcac)
and AT1_R (atgtgctgagcctttttcctt), annealing at 56 C. The
PCR product was purified on silica-membrane columns
(Nucleospin gel and PCR clean up, Macherey–Nagel) and
digested with NruI (New England Biolabs), run on a 1.5 %
agarose gel and visualized with ethidium bromide. UBP1
and UBP1-R131L were amplified from STIB900 and
STIB900-M, respectively, with the primers UBP1_F
(ccgctctagatctcaggttccactggcttc) and UBP1_R
(ccgcggatcctcatttacgggcaggccgac).
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Plasmid construction, transfection and knock-out
generation
The gene encoding the AT1-G430R mutant was amplified
by PCR from genomic DNA of STIB900-P and the product
was ligated into the expression vector pHD1336 [38] to
give pHDK68. The plasmid was verified by Sanger
sequencing (Source BioScience, Nottingham, UK) for the
presence of the expected mutation and linearized with NotI
prior to transfection into T. b. brucei clone B48, which lack
the AT1 gene and the high-affinity pentamidine transporter
[16]. B48 parasites were washed in Human T Cell Solution
for transfection with an Amaxa Nucleofector [39]. Trans-
fectants were cloned by limiting dilution in standard HMI-
11 medium [40] containing 5 lg/ml blasticidin for selec-
tion of the positive transfectants. Correct integration of the
expression cassettes was tested by PCR.
Trypanosoma brucei rhodesiense 2T1 aqp2/3-/- cells
were assembled using a I-SceI meganuclease-based gene-
conversion approach. Briefly, blasticidin deaminase (BSD)
and neomycin-phosphotransferase (NPT) cassettes were
used to replace the AQP2/3 locus. Meganuclease cleavage
of the NPT cassette was then used to trigger replacement
with, and duplication of, the BSD cassette. AT1 was dis-
rupted in the resulting 2T1 aqp2/3-/- cells by replacing the
first allele of the 1392 bp ORF with PCR-amplified NPT
containing 100 bp overhangs identical to the UTRs of AT1,
followed by selection with 5 lg/ml G418. The second
allele was replaced with PAC plus 500 bp AT1 UTR on
either end, followed by selection with 0.1 lg/ml pur-
omycin. Homozygous deletion of AT1 was verified by PCR
(Figure S1).
Reverse genetics of UBP1
For overexpression of UBP1, the UBP1 and UBP1-R131L
PCR products were cloned into pRPaiGFPx [41] via XbaI
and BamHI. T. b. brucei 2T1 cells [42] were transfected
with AscI-digested plasmids in Tb-BSF nucleofection
buffer [43] using the Amaxa nucleofector (Lonza) with
program Z-001. Transfectants were cloned by limiting
dilution and selected with 2.5 lg/ml hygromycin. PCR and
Sanger sequencing confirmed correct integration and
sequence of the transgene.
To introduce the mutant UBP1-R131L in 2T1 cells
in situ, a plasmid carrying the mutation and a blasticidin
resistance gene (BSD) in the 50 UTR of UBP1, used as a
selection marker, was constructed (Supplementary Fig-
ure S3A). The synthetic DNA was obtained from GenScript
(Piscataway Township, NJ, USA), integrated between the
HindIII and BamHI sites of cloning plasmid pUC57. DNA
for transfection was prepared by PCR amplification of the
insert using primers BLA_UBP1mut_F1
(ttgcattcgctcctttccct) and BLA_UBP1mut_R1 (ccttcag-
tagtttgttgagg) and subsequent purification as described
above. 2T1 cells were transfected with an Amaxa Nucleo-
fector using program Z-001 and clones were obtained as
described above. Cells were selected with 5 and 10 lg/ml
blasticidin. Correct homozygous integration was verified by
PCR (Supplementary Figure S3B) and Sanger sequencing
(Fig. 6b).
SDS-PAGE and western blotting
Cells were lysed in NUPAGE LDS sample buffer (Life
Technologies) and samples were loaded on precast 4–12 %
Bis–Tris Gradient Gels (NuPAGE Novex, Life Tech-
nologies) in MES running buffer and transferred to
nitrocellulose membranes using the iBlot dry-blotting sys-
tem (Novex, Life Technologies). Membranes were
blocked in 5 % milk in PBS/Tween-20 and incubated with
primary antibodies in 5 %milk in TBS/Tween-20 overnight
at 4 C. Membranes were washed and incubated with per-
oxidase-conjugated secondary antibodies in 5 % milk PBS/
Tween-20 for 2 h at room temperature. Blots were devel-
oped using the ECL Western Blotting Substrate (Pierce)
using a ChemiDocTM MP Gel Imaging System (Biorad).
Primary Antibodies used: rabbit anti-GFP (Abcam, Ab290),
mouse anti-BiP (kind gift of Prof A. Schneider). Secondary
Antibodies used: goat anti-rabbit (SouthernBiotech:
4050-05), polyclonal rabbit anti-mouse HRP (Dako, Baar,
Switzerland).
Results
Phenotypic profiling of high-level melarsoprol–
pentamidine cross-resistance
Before venturing into genomics we performed an in-depth
phenotypic profiling of the parental T. b. rhodesiense
STIB900 and its two drug-resistant derivatives STIB900-M
and STIB900-P. Drug sensitivities were quantified as 50 %
inhibitory concentrations (IC50) towards the five clinical
trypanocides (pentamidine, suramin, melarsoprol, eflor-
nithine, and nifurtimox), two clinical candidates
(fexinidazole and the diamidine DB75), and selected
experimental compounds (Table 1). STIB900-M and
STIB900-P exhibited similar resistance profiles, namely
strong MPXR with cross-resistance to other diamidines
(i.e., diminazene aceturate and DB75) and adenosine ana-
logs [cordycepin (30-deoxyadenosine), tubercidin (7-
deazaadenosine), vidarabine (adenosine arabinoside)]. The
melarsoprol-selected line generally had higher resistance
factors than the pentamidine-selected line to the adenosine
analogs and other typical AT1 substrates [23] such as DB75
F. E. Graf et al.
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and melarsoprol itself, though not all the differences were
statistically significant (p\ 0.004 in Anova one-way
analysis of variance followed by Tukey’s multiple com-
parison test; Table 1). On the other hand, STIB900-P was
cross-resistant to the adenine analog aminopurinol (not a
AT1 substrate [44]) whereas STIB900-M was not (Table 1).
Neither line was resistant (p\ 0.004 in Anova plus Tukey’s
test) to suramin, nifurtimox, fexinidazole, or phenylarsine
oxide, a hydrophobic arsenical that diffuses across the
plasma membrane [13]. Surprisingly, both STIB900-M and
STIB900-P were significantly hypersensitive to eflornithine
(difluoromethylornithine, DFMO). This unexpected result
is consistent with the observation that eflornithine resis-
tance caused by loss of the amino acid transporter TbAAT6
was accompanied by hypersensitivity to pentamidine [45].
TbAAT6 was not overexpressed in the resistant lines (see
below). The in vitro population doubling times without drug
were 9.4 ± 0.3 h and did not significantly differ between
the tree lines (p[ 0.05 in Anova one-way analysis of
variance followed by Tukey’s multiple comparison test).
Transcriptomic profiling indicates loss of expression
of transporter genes
Quantitative transcriptomics served as a first tool to
investigate the strong MPXR phenotype of T. b. rhode-
siense STIB900-P and STIB900-M at the molecular level.
For this purpose we used the ‘spliced leader trapping’
(SLT) adaptation of Illumina RNA-Seq [29], exploiting the
fact that all trypanosomal mature mRNAs carry the same
39 nt leader sequence spliced in-trans to their 50 end, a
peculiarity of trypanosomatids [46]. SLT is optimally sui-
ted to quantify steady-state mRNA levels by counting the
number of reads per transcript because all the reads stem
from the transcription start sites. Figure 1 shows one of two
independent experiments; all data are included in the
supplementary Excel file Graf_S1.xlsx. Overall, there was
very little variance between the drug-resistant lines and
their sensitive parent (Fig. 1a). Four genes were overex-
pressed in STIB900-P compared to STIB900 and STIB900-
M, all of which are neighboring genes on chromosome 6
encoding for VSGs. This confirms that antigenic variation
also takes place in vitro, but new variants rarely become
fixed in the population because of continuous dilution of
the growing cultures. Apart from these VSG, no genes were
significantly overexpressed in the resistant T. b. rhode-
siense lines—including TbMRPA, an export pump that
confers resistance to melarsoprol when overexpressed
ectopically [47, 48]. The adenosine transporter AT1 and six
adjacent genes on the telomere of chromosome 5 [49] were
not expressed above detection limit in STIB900-M
(Fig. 1b). This is in agreement with the reported absence of
AT1 in STIB900-M [24] and is indicative of a larger
deletion at the AT1 locus. The aquaglyceroporin AQP2
appeared not to be expressed above detection limit in either
resistant line (Fig. 1c). However, the automated mapping
of the reads [29] was ambiguous because of the high degree
of similarity between AQP2 and AQP3 at their 50 ends
Table 1 In vitro drug sensitivity profiles
IC50 ± standard deviation [nM] p value Resistance factor
STIB900 STIB900-P STIB900-M STIB900 vs.
900-P
STIB900 vs.
900-M
STIB900-P vs.
900-M
STIB900-P to
900
STIB900-M to
900
Melarsoprol 6.0 ± 3.4 84 ± 52 170 ± 63 0.040 \0.0001 0.026 14 28
Pentamidine 2.8 ± 0.8 130 ± 69 210 ± 93 0.033 0.0008 0.17 47 76
Diminazene 3.8 ± 1.5 18 ± 5.4 25 ± 10 0.012 0.0003 0.25 4.7 6.5
DB75 3.7 ± 0.9 22 ± 8 64 ± 17 0.046 \0.0001 \0.0001 5.9 17
Suramin 135 ± 62 76 ± 32 125 ± 25 0.11 0.92 0.21 0.6 0.9
Nifurtimox 1100 ± 550 1100 ± 460 1500 ± 620 0.99 0.51 0.55 1.0 1.4
Fexinidazole 3200 ± 1100 2500 ± 980 6100 ± 2500 0.80 0.041 0.013 0.8 1.9
Eflornithine 5200 ± 1400 1300 ± 640 2700 ± 480 \0.0001 0.0033 0.094 0.3 0.5
Cordycepin 0.46 ± 0.1 2.2 ± 0.54 7.0 ± 1.5 0.026 \0.0001 \0.0001 4.7 15
Vidarabine 265 ± 108 400 ± 52 650 ± 190 0.24 0.0006 0.0186 1.5 2.5
Tubercidin 26 ± 6 100 ± 19 4300 ± 1000 0.97 \0.0001 \0.0001 3.8 163
Aminopurinol 1500 ± 190 5400 ± 1100 2000 ± 630 \0.0001 0.58 \0.0001 3.6 1.3
Phenylarsine 0.52 ± 0.13 0.65 ± 0.11 0.75 ± 0.08 0.26 0.028 0.45 1.3 1.4
Mean IC50 values, p values of Anova one-way analysis of variance followed by Tukey’s multiple comparison test, and resistance factors. Taking
into account the 13 independent tests of the different drugs, the Bonferroni-corrected threshold for significance is p\ 0.00385
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(Fig. 2). The short Illumina reads were manually mapped
to AQP3 since the deletion of AQP2 was confirmed by the
longer 454 reads (Fig. 2). Apart from AT1 plus adjacent
genes and AQP2, no genes were significantly under
expressed in the resistant lines.
A reference genome sequence of the T. b. rhodesiense
drug-sensitive parent
Before exploring the mutations underlying the strong
MPXR phenotype of STIB900-P and STIB900-M by
comparative genomics, we had to generate a good-quality
draft genome of the susceptible parent T. b. rhodesiense
STIB900. Genomic DNA was isolated from bloodstream-
form trypanosomes grown in mice. The obtained gDNA
was verified to be free of mouse DNA by PCR with primers
for mouse GAPDH. Paired-end Illumina reads generated
on the HiSeq platform were mapped to the core chromo-
somes of T. b. brucei TREU927 with an average coverage
of 53 fold. The vast majority of gene models (9692 of
9722) were transferred from T. b. brucei TREU927 to the
assembled T. b. rhodesiense STIB900 genome, identifying
a total of 112,565 high-quality single-nucleotide poly-
morphisms (SNP) between these two genomes. In protein-
coding regions there were 46,453 SNPs, of which 19,575
non-synonymous. As expected, the assembled T. b.
rhodesiense STIB900 genome contained the SRA gene
(serum resistance-associated; Tb927.9.17380), whose pro-
duct neutralizes ApoL1, the trypanolytic factor of human
serum that protects humans from infection by T. b. brucei.
The genome reference strain T. b. brucei TREU927 con-
tains a dysfunctional SRA ortholog [50, 51].
.....
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Fig. 1 Comparative transcriptomics. a Scatter plots of normalized
read counts from RNA sequencing data using the spliced leader
trapping protocol. The increment of one allowed logarithmic repre-
sentation also for genes that had zero sequence tags. Genes that are
not expressed in the resistant lines are indicated. Note the VSG switch
in STIB900-P. b View of the AT1 locus with read counts per gene.
c View of the AQP2/AQP3 tandem locus with read counts per gene
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Comparative genomics confirms the loss
of transporter genes
The assembled genome sequence of T. b. rhodesiense
STIB900 was used as a reference to identify mutations in
the resistant derivatives STIB900-P and STIB900-M.
Genomic DNA was isolated from bloodstream-form try-
panosomes harvested from infected mice. The known
absence of AT1 from STIB900-M was used for diagnostic
PCR of the purified gDNA to verify that there had been no
contaminations. Roche-454 sequencing libraries were
generated for all three lines, obtaining *1.5 million high-
quality reads for each genome, corresponding to a 20-fold
coverage (Table S1). The Roche/454 reads from STIB900-
M and STIB900-P were mapped to the assembled STIB900
genome with an overall coverage of 83 % (DP4 C5). SNPs
and indels were identified with SAMtools and with self-
developed Perl scripts. All identified SNPs, indels, and
gene deletions were inspected manually using Artemis
[37]. Overall, there were remarkably few mutations in
STIB900-M and STIB900-P relative to their parent
STIB900 (Table 2). Only one coding point mutation was
found in both resistant lines (in the gene UBP1, see below).
Both lines carried a deletion of about 1.8 kb at the AQP2/
AQP3 locus (Fig. 2a), causing loss of the aquaglyceroporin
AQP2 but not of AQP3. The deletion was confirmed by
PCR on genomic DNA followed by sequencing of the
products (not shown). T. b. rhodesiense STIB900-M had
not only lost the gene AT1 (Tb927.5.286b), as previously
published [24], but a whole region of over 25 kb encom-
passing AT1 and the adjacent genes Tb927.5.288b
(ribulose-phosphate 3-epimerase, putative), Tb927.5.289b
(hypothetical protein), Tb927.5.291b (variant surface gly-
coprotein-related), and Tb927.5.292b (hypothetical
protein).
A point mutation that renders TbAT1 non-
functional is heterozygous in STIB900-P
Trypanosoma brucei rhodesiense STIB900-P still pos-
sessed AT1 but the gene contained a non-synonymous
substitution, G1288C, resulting in the mutation of
glycine430 to arginine. The identified point mutation was
confirmed with Sanger sequencing and by restriction digest
of the AT1 PCR product, since the mutation generated an
endonuclease NruI site (tcgcga; Fig. 3). The facts that the
AT1 PCR products from genomic DNA of STIB900-P (1)
were not digested completely (Fig. 3), and (2) after cloning
and sequencing did not all contain the C at position 1288
(not shown), indicate that STIB900-P is heterozygous for
the mutation G1288C. The AT1-G430R mutant was func-
tionally characterized in T. b. brucei B48, a mutant which
lacks high-affinity transport of melarsoprol and pen-
tamidine [16, 52]. B48 bloodstream-form cells were
Fig. 2 Loss of AQP2 from the resistant lines. a Roche-454 sequenc-
ing reads generated from genomic DNA of STIB900-P and STIB900-
M mapped to the reference sequence of STIB900 as visualized with
BamView [59]. The gene AQP2 is missing in both STIB900-P and
STIB900-M. b The tandem nature of the AQP2/AQP3 locus on
chromosome 10 as illustrated by a dot plot of the STIB900 reference
sequence from (a) on the x axis vs. the sequence of AQP3 on the y
axis (made with GEPARD [60] and a word length of 10). The genes
AQP2 and AQP3 are highly similar (82 % global identity) as depicted
by the diagonal on the right
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transfected with wildtype AT1, G430R mutant AT1, and
empty vector as a control. Expression of wildtype AT1
strongly sensitized the B48 transfectants to melarsoprol,
pentamidine, and diminazene aceturate (Berenil), whereas
G430R mutant AT1 did not (Fig. 4). This demonstrates that
the point mutation renders AT1 non-functional with respect
to drug transport.
Concomitant deletion of AQP2 and AT1 does
not phenocopy the high-level MPXR
The contributions to MPXR of either AQP2 or AT1 alone
have been extensively studied [11, 53]. To try and phe-
nocopy T. b. rhodesiense STIB900-P and STIB900-M,
respectively, we have generated heterozygous and
homozygous T. b. brucei at1 null lines (Supplementary
Figure S1) in a aqp2/aqp3 null background [17]. The four
lines 2T1 (parental), 2T1-aqp2/aqp3-/-, 2T1-aqp2/
aqp3-/--at1?/-, and 2T1-aqp2/aqp3-/--at1-/- were
characterized regarding their growth and drug sensitivities.
The four lines grew equally well in vitro with population
doubling times of around 7.0 ± 0.5 h (p[ 0.05 in Anova
one-way analysis of variance followed by Tukey’s multiple
comparison test), indicating that simultaneous loss of AT1,
AQP2, and AQP3 does not bear a fitness cost in vitro. In
agreement with previous findings [17], the IC50 of pen-
tamidine increased by about 15 fold in the absence of
AQP2. Heterozygous deletion of AT1 further increased the
resistance factor to 20, homozygous deletion to 35 (Fig. 5).
The susceptibilities of the four strains to melarsoprol did
not follow such a pronounced pattern, with moderated
resistance factors of 2–2.5 (Fig. 5). Clearly, the MPXR
resistance factors obtained through simultaneous knock-out
of AT1 and AQP2 were below those of T. b. rhodesiense
STIB900-M and STIB900-P (Table 1), indicating that
further mutations must contribute to the high-level MPXR
phenotype observed in those lines.
Testing of the RNA-binding protein UBP1 as a new
candidate resistance gene
In view of the very small number of non-synonymous
SNPs (Table 2), the finding that the two independently
selected lines, STIB900-P and STIB900-M, were
homozygous for the same point mutation, Arg131 to Leu, in
the uridine-rich-binding protein 1 (UBP1, Tb927.11.500;
Table 2) was of particular interest. UBP1 is an RNA-
binding protein with a single, conserved RNA recognition
motif (RRM, Fig. 6a), whose structure has been deter-
mined for its ortholog in Trypanosoma cruzi [54]. Arg131 of
TbUBP1 corresponds to Arg113 of TcUBP1 in T. cruzi and
lies within the ß4–ß5 hairpin of the RRM (Fig. 6a) that is
involved in RNA binding [54]. To test the impact of the
mutation R131L on TbUBP1 function, we first generated
two stable T. b. brucei 2T1 cell lines overexpressing either
GFP-UBP1-wt or GFP-UBP1-R131L at a single specific
locus within the rRNA spacer in a tetracycline (Tet)-in-
ducible manner [42]. Both lines still possessed the
endogenous UBP1 alleles. Overexpression of GFP-UBP1-
wt for longer than 24 h caused a strong growth defect
Table 2 SNP statistics
STIB900-M vs. STIB900 STIB900-P vs. STIB900
Overall CDS NS Overall CDS NS
Chr1 0 0 0 2 0 0
Chr2 0 0 0 0 0 0
Chr3 0 0 0 1 0 0
Chr4 0 0 0 0 0 0
Chr5 2 0 0 1 Tb927.5.286b G430R
Chr6 1 0 0 0 0 0
Chr7 0 0 0 1 0 0
Chr8 1 0 0 0 0 0
Chr9 6 0 0 5 Tb927.9.8310* D31G
Chr10 0 0 0 0 0 0
Chr11 2 Tb927.11.500 R131L 4 Tb927.11.500 R131L
Total 12 1 1 14 3 3
Single-nucleotide polymorphisms between the drug-resistant T. b. rhodesiense lines and their parent STIB900 (CDS coding sequence, NS non-
synonymous)
* This gene is no longer part of TriTrypDB
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(Supplementary Figure S2A), which is in agreement with
previous findings [55]. Interestingly, overexpression of
GFP-UBP1-R131L did not cause a growth phenotype
(Figure S2A). However, the GFP-UBP1-R131L overex-
pressing trypanosomes were slightly but significantly
hypersensitive to pentamidine as compared to non-induced
cells (IC50 of 1.2 nM vs. 2.7 nM; Figure S2B). We do not
have an explanation for this counter-intuitive result—
which has to be interpreted with caution due to the lack of a
control since overexpression of wildtype UBP1 was toxic
to the trypanosomes. Attempting to test the role of the
identified mutation in a more physiological context, we
introduced the mutant gene UBP1-R131L in T. b. brucei
2T1 cells in situ. A blasticidin resistance gene (BSD) was
added to the 50 UTR of the UBP1 gene together with the
mutation encoding for Leu131 (Supplementary Fig-
ure S3A). Antibiotic pressure allowed selection of two
homozygous clones (designated H and L) without the need
for a second round of transfection (Fig. 6b, Supplementary
Figure S3B). However, neither of the two clones exhibited
a significantly reduced sensitivity to melarsoprol or pen-
tamidine as compared to parental 2T1 cells (Fig. 6c).
Discussion
Cross-resistance of African trypanosomes to melarsoprol
and pentamidine (MPXR) is a well-known phenomenon
[11]. Here we perform in-depth phenotypic and genotypic
profiling of two lab-derived T. b. rhodesiense mutants with
most pronounced MPXR phenotypes: STIB900-P, selected
with pentamidine, and STIB900-M, selected with melar-
soprol. The two independently selected lines exhibited
similar—but not identical (Table 1)—resistance profiles,
extending MPXR to other diamidines and adenosine ana-
logs, but not to suramin or nifurtimox.
Very few mutations had become fixed in the drug-se-
lected lines in the 2 years’ course of selection (Table 2),
and very few genes were differentially expressed in the
resistant lines compared to the sensitive parent (Fig. 1).
Fig. 3 Loss or mutation of AT1 in the resistant lines. a Genomic 454
reads of STIB900-P and STIB900-M mapped to STIB900 visualized
for the AT1 locus on chromosome 5 using BamView [59] (smaller
scale for STIB900-M). There is a deletion of AT1 in STIB900-M and
a coding point mutation in STIB900-P (red). b AT1 PCR products
(1636 bp) were amplified from genomic DNA of STIB900 and
STIB900-P, and digested with the endonuclease NruI. G1288C
mutant alleles are cut to fragments of 1339 and 257 bp. STIB900-P
appears to be heterozygous for the mutation
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The only striking difference was the complete absence of
RNA-Seq reads for AQP2 in STIB900-M and STIB900-P,
and for AT1 and neighboring genes in STIB900-M. Both
STIB900-M and STIB900-P carried a deletion of the AQP2
locus (Fig. 2). This ‘natural knock-out’ of AQP2 was
probably due to homologous recombination with the
neighboring, highly similar gene AQP3 (Fig. 2), accom-
panied by loss of genetic material. Cases of truncation or
chimerization of AQP genes in drug-resistant T. brucei had
been reported previously [17, 20, 21, 56]. T. b. rhodesiense
STIB900-M also carried a large deletion on chromosome
five encompassing AT1 and six adjacent genes (Fig. 3), a
gene loss possibly facilitated by their telomeric location.
STIB900-P had a non-synonymous point mutation in AT1
changing Gly430 to Arg (Fig. 3). Expression of wildtype
and G430R-mutant AT1 in a T. b. brucei loss of transport
mutant demonstrated that the AT1-G430R did not transport
melarsoprol or diamidines (Fig. 4). The finding that
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Fig. 4 Functional characterization of G430R mutant AT1. The genes
AT1, AT1-G430R, and an empty vector control (ev. ctrl) were
expressed in the T. b. brucei B48 mutant [16]. Transfectant clones
were tested in vitro for their sensitivity to the known AT1 substrates
pentamidine, cymelarsan, and diminazene. Phenylarsine oxide (PAO)
was included as a negative control that is not a AT1 substrate. The
IC50 values are from 5 to 8 independent experiments; error bars are
standard errors of the mean. The small letters indicate significance
groups (p\ 0.05) as determined by Anova one-way analysis of
variance followed by Tukey’s multiple comparison test
Fig. 5 AT1/AQP2 double knock-out in T. brucei. In vitro drug
sensitivities were determined for pentamidine and melarsoprol on
parental 2T1 cells, 2T1-aqp2-/-, 2T1-aqp2-/--AT1?/-, and 2T1-
aqp2-/--at1-/-. Bars are the average IC50 of at least four indepen-
dent experiments, each performed in triplicate. Error bars indicate the
standard error of the mean
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STIB900-P is heterozygous for the mutation might explain
its milder MPXR phenotype than STIB900-M (Table 1).
These results are the best evidence to date that the MPXR
models developed in the non-human infective trypanosome
T. b. brucei hold true in T. b. rhodesiense, the causative
agent of sleeping sickness in East Africa, and that selection
for high-level resistance to melarsoprol and pentamidine
can lead to loss of both known drug transporters.
To investigate the combined contribution of AQP2 and
AT1 to drug sensitivity, we constructed T. b. brucei hetero-
and homozygous at1 null mutants in a aqp2/aqp3 null
background. The effects of the mutations were additive
regarding pentamidine sensitivity, with a maximal resis-
tance factor of 35 for the double null mutant of at1 and
aqp2 (Fig. 5). The phenotypes with respect to melarsoprol
were less pronounced, as the loss of AT1 did not further
increase the melarsoprol resistance of the aqp2 null mutant
(Fig. 5). The conclusion from these experiments is that
concomitant deletion of AQP2 and AT1 does not com-
pletely phenocopy the strong MPXR phenotypes of T. b.
rhodesiense STIB900-M and STIB900-P, demonstrating
that further genes must be involved. Only one additional
gene was affected by a mutation in both resistant lines: the
RNA-binding protein UBP1.
Trypanosoma brucei rhodesiense STIB900-M and
STIB900-P both carried the mutation R131L in UBP1,
which was absent in the parent and must have been
acquired by the resistant lines independently. The precise
function of UBP1 is unknown, but it has been implicated in
regulation of mRNA levels [55]. Based on the alignment to
TcUBP1 from T. cruzi, Arg131 of TbUBP1 is predicted to
be critical for RNA binding (Fig. 6a), suggesting that
Leu131 may impair TbUBP1 function. Complete loss of
UBP1 function may be lethal, as indicated by RNAi-me-
diated knock-down of UBP1 and UBP2 [55]. TcUBP1 is a
cytoplasmic protein in epimastigotes of T. cruzi [57].
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Fig. 6 In situ mutation of UBP1 in T. b. brucei. a Alignment of the
predicted RNA recognition motif (RRM) of UBP1 from STIB900,
STIB900-M, and STIB900-P alongside Trypanosoma cruzi UBP1.
The mutation of the conserved Arg131 to Leu is highlighted in the
alignment and Arg131 is indicated with an arrow in the published
structure of TcUBP1. The full length TcUBP1 is 224 aa but a
truncated version (1–139) including the RRM (35–126) was used to
determine the structure [54]. Swiss model [61] was used to visualize
the structure. b Sanger sequencing electropherograms of UBP1
amplified from genomic DNA of parental 2T1 cells and two
transgenic clones H and L, showing the nucleotides that encode
amino acids 130–132. c In vitro drug sensitivities (IC50 ± standard
deviation; n = 12) for melarsoprol and pentamidine determined with
the Alamar blue assay for parental 2T1 cells and the two transgenic
clones H and L. There was no significant difference in drug sensitivity
between the three lines (Anova one-way analysis of variance followed
by Tukey’s multiple comparison test)
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Intriguingly, TcUBP1 was shown to accumulate in the
nucleus when the trypanosomes were under arsenite stress,
and mutations affecting RNA binding prevented nuclear
accumulation of TcUBP1 [57]. TbUBP2, which shares
73 % global identity with TbUBP1, had appeared as a
secondary hit in a genome-wide RNAi screen for pen-
tamidine resistance in T. brucei [58]. While such previous
findings may support a possible role of UBP1 in drug
resistance, our reverse genetic approaches did not. Non-
physiological overexpression of UBP-Leu131-GFP in T. b.
brucei bloodstream forms even caused a slight hypersen-
sitivity to pentamidine (Figure S2B). However, this needs
to be interpreted cautiously since, in agreement with a
previous report [55], overexpression of the ‘wildtype’
UBP1-GFP fusion protein was lethal (Figure S2A). More
physiological in situ expression of the mutant UBP1 in T.
b. brucei did not affect the sensitivity to melarsoprol or
pentamidine (Fig. 6c). In summary, if the mutation Arg131
to Leu in UBP1 contributes to drug resistance at all, then it
does so only in the context of the described loss of AQP2
and/or AT1.
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